Greater London Authority

ICO reprimands London Mayor's Office for Policing and Crime for complaint web form error

Retrieved on: 
Tuesday, April 2, 2024
PECR, Greater London Authority, Metropolitan, Address, Information, Freedom, Telecommunications, EIR, Privacy, ICO, Complaint, MOPAC, Environmental Information Regulations 2004, Information privacy, Data wrangling, GLA, FOIA, Met, Cryptocurrency

The London Mayor's Office for Policing and Crime (MOPAC), which is responsible for oversight of the Met, had two forms available on its website - one to contact the Victims Commissioner for London and another to raise a complaint about how the Met had handled their original complaint.

Key Points: 
  • The London Mayor's Office for Policing and Crime (MOPAC), which is responsible for oversight of the Met, had two forms available on its website - one to contact the Victims Commissioner for London and another to raise a complaint about how the Met had handled their original complaint.
  • The incident occurred due to an error by Greater London Authority (GLA), which runs the London.gov.uk website, including MOPAC's pages and webforms.
  • Between 11-14 November 2022, a member of GLA intended to give four members of staff at MOPAC permission to access information shared through the web forms.
  • - To report a concern to the ICO telephone our helpline 0303 123 1113 or go to ico.org.uk/concerns.

How metro mayors are getting things done -- even if they have limited money and power

Retrieved on: 
Wednesday, June 28, 2023
Shakespeare North, Travel, Housing, Gove, Tourism, Burnham, Lord, Manchester Piccadilly station, Culture, Devolution, Policy, Greater London Authority, Whitehall, Personality, Government, Manchester Evening News, 2021 Liverpool City Region mayoral election, Local government, Collection, LCR, Economic development, Frustration, HS2, City, Growth, Ageing, Health, Film industry, Drug, Tunnel, Renewable energy, Rail transport, Warehouse, Liverpool City Region

The further ceremonial title of Lord Mayor was conferred by royal letters patent on the leaders of the nation’s biggest cities.

Key Points: 
  • The further ceremonial title of Lord Mayor was conferred by royal letters patent on the leaders of the nation’s biggest cities.
  • Metro mayors– of which there are now nine – are voted in by residents of all the local authorities of a combined authority.
  • Our new book, Devolution in Greater Manchester and Liverpool City Region, asks if the metro mayors amount to a constitutional revolution in English local government or a limited and temporary experiment.

Personality matters

    • Along with his ten council leaders, he criticised the imposition of tier-three restrictions as discriminatory.
    • Working with the council leaders or directly elected mayor of each local authority in the region, no matter their political allegiance, is crucial to metro mayors’ success.
    • As are relationships with the political parties and interest groups and, ultimately, the electorate – none of which are static.
    • Although metro mayors hold devolved powers distinct from those of local authorities, these do not automatically translate into the ability to get things done.

Transactional politics

    • Quite how though varies depending on the combined authority.
    • Greater Manchester was the only combined authority to have health and social care included in its first devolution deal in 2014.
    • But Burnham and Rotheram went ahead regardless, effectively expanding their role beyond what the government’s deal had laid out.

Lack of power

    • He has developed the Opportunity Pass, to provide free bus travel for 16-18 year olds, along with free access to various culture and leisure facilities.
    • Since November 2018, Liverpool too has provided free bus travel, for apprentices aged 19-24.
    • But our interviewees expressed frustration at setbacks related to a lack of power and resources which have made policy wins hard to achieve.
    • On the question of HS2, the power that central government retains has been evident.

FLAP Data Center Industry to 2027 - Adoption of 5G Network Services, Artificial Intelligence and Cloud-Based Services Drives Growth

Retrieved on: 
Sunday, January 22, 2023
USD, Government, Artificial intelligence, Microsoft, Digital Realty, Education, Ørsted, Greater London Authority, London Gateway, IBM, GTR, Ali Baba, CPPA, Equinix, Investment, Iron Mountain, Health, AWS, Dartford, Cushman & Wakefield, Cushman, BFSI, T-Mobile, EE, Noise, Electricity, Deutsche Telekom, Telecom, Wind, Greater London, UK Government G-Cloud, VodafoneZiggo, Central College (Iowa), CloudHQ, Vodafone, Growth, OVHcloud, Internet of things, Organization, Telehouse Europe, Free-trade zone, Carbon, KPN, City, CyrusOne, Cryptocurrency, Retail, Renewable energy, Commercial property, Tencent, Oracle

The FLAP data center market is one of Western Europe's major data center markets.

Key Points: 
  • The FLAP data center market is one of Western Europe's major data center markets.
  • The market is witnessing the growth of investments due to the adoption of 5G network services, Artificial Intelligence, cloud-based services, IoT and big data.
  • Free Trade Zones, Special Economic Zones, and industrial parks majorly attract investment in the FLAP data center market.
  • Some of the real estate companies in the FLAP industry are involved in developing the data center campus.

FLAP Data Center Market 2022 to 2027: Investment Analysis & Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
VoIP, Software, Carriers and Services, Mobile, Wireless, Networks, Internet, Hardware, Data Management, Technology, Security, Other Technology, Telecommunications, Cushman, Telecom, Greater London Authority, Wind, Ali Baba, Cushman & Wakefield, EE, London Gateway, Government, IOT, KPN, Deutsche Telekom, Carbon, T-Mobile, Vodafone, Artificial intelligence, City, Growth, VodafoneZiggo, OVHcloud, IBM, Microsoft, AWS, Dartford, Greater London, USD, Electricity, Investment, Free-trade zone, Renewable energy, Communications satellite, Tencent, Oracle

The "FLAP Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FLAP Data Center Market - Investment Analysis & Growth Opportunities 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The FLAP data center market is expected to grow at a CAGR of 2.86% from 2021-2027.
  • The FLAP data center market is one of Western Europe's major data center markets.
  • Free Trade Zones, Special Economic Zones, and industrial parks majorly attract investment in the FLAP data center market.

Mahana Therapeutics Selected for Prestigious Digitalhealth.London Accelerator Program

Retrieved on: 
Tuesday, January 18, 2022
Mental Health, Health, Technology, Other Health, Software, Pharmaceutical, Biotechnology, CE marking, Ministry, Patient, European Regional Development Fund, Accelerator, Technology, CBT, Union, ERDF, Pan-Mass Challenge, Adoption, Community, CW, Population, Mass, Solution, NHS, Irritable bowel syndrome, Health, Ministry of Housing, Communities and Local Government, Cognitive behavioral therapy, SME, Therapy, Program, Greater London Authority, MedCity, European Structural and Investment Funds, Multimedia, NHSX, Local government, IBS, FDA, Economic development, UCLPartners, Pharmaceutical industry, Health insurance, Housing, Mahana Therapeutics, DigitalHealth.London Accelerator, European Regional Development Fund, MAHANA THERAPEUTICS, DIGITALHEALTH.LONDON ACCELERATOR, EUROPEAN REGIONAL DEVELOPMENT FUND

Mahana Therapeutics , a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.Londons Accelerator programme .

Key Points: 
  • Mahana Therapeutics , a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.Londons Accelerator programme .
  • The program will help Mahana Therapeutics better engage with the NHS to accelerate adoption of Mahana IBS in clinical practice.
  • We are excited to join this prestigious program to accelerate adoption of and experience with Mahana IBS within the NHS.
  • Mahana Therapeutics is a leading developer of effective prescription digital therapeutics that are designed to empower patients with chronic conditions to live fuller lives.

AECOM secures positions on Transport for London engineering consultancy framework

Retrieved on: 
Wednesday, November 24, 2021
Consulting, Rail, Professional Services, Transport, Public Transport, Security (finance), Coronavirus, Insurance, Sale, Environment, Consultant, Industry, NYSE, Transport, Compliance, Greater London Authority, Engineering, Professional services, Cyprus Securities and Exchange Commission, Program, City, View, TfL Rail, Communication, Risk, Culture, Managed services, Water, List of cycle routes in London, ACM, Failure, Transport for London, Travel, ECF, Civil engineering

AECOM (NYSE: ACM), the worlds trusted infrastructure consulting firm, today announced it has won places on over 30 Lots of the Transport for London (TfL) Engineering Consultancy Framework (ECF), including places on the strategic Multidisciplinary Engineering Services and Multidisciplinary Rail Engineering Services Lots.

Key Points: 
  • AECOM (NYSE: ACM), the worlds trusted infrastructure consulting firm, today announced it has won places on over 30 Lots of the Transport for London (TfL) Engineering Consultancy Framework (ECF), including places on the strategic Multidisciplinary Engineering Services and Multidisciplinary Rail Engineering Services Lots.
  • The four-year framework will be the primary means of accessing engineering consultancy services for TfL, the Greater London Authority, all 32 London borough councils and the City of London.
  • This important framework builds on our long-term relationship with TfL, expanding our scope of services and technical disciplines available to them, said Lara Poloni, AECOMs president.
  • The framework Lots cover multidisciplinary engineering services, specialist engineering services, engineering architectural services, highways engineering and rail engineering.

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Retrieved on: 
Thursday, September 23, 2021
Health, GMP, Therapy, Clinical trial, Transplant, Ministry, Quell, Innovate UK, Degenerative disease, Greater London Authority, Human resource policies, Local government, Patient, European Structural and Investment Funds, Gene, Good manufacturing practice, Immune system, Environment, Company, European Union, Liver transplantation, Growth, Community, Innovation, Medicine, Cell, Union, European Regional Development Fund, Ministry of Housing, Communities and Local Government, Economic development, Catapult, Industry, Pharmaceutical industry, Vaccine

LONDON, Sept. 23, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, todayannounced it has entered a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult).

Key Points: 
  • LONDON, Sept. 23, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, todayannounced it has entered a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult).
  • The collaboration will expand Quell's clinical manufacturing capabilities and capacity in one of the recently opened specialist large-scale manufacturing modules at CGT Catapult's manufacturing innovation centre in Stevenage, UK.
  • The Stevenage Manufacturing Innovation Centre allows companies developing cell and gene therapies to develop their manufacturing processes at scale to Good Manufacturing Practice (GMP) standards.
  • "Quell is a ground-breaking company with leading technology which is progressing engineered Treg cell therapies into the clinic.

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Retrieved on: 
Thursday, September 23, 2021
Health, GMP, Therapy, Clinical trial, Transplant, Ministry, Quell, Innovate UK, Degenerative disease, Greater London Authority, Human resource policies, Local government, Patient, European Structural and Investment Funds, Gene, Good manufacturing practice, Immune system, Environment, Autoimmunity, Company, European Union, Liver transplantation, Growth, Community, Innovation, Medicine, Cell, Union, European Regional Development Fund, Ministry of Housing, Communities and Local Government, Economic development, Catapult, Industry, Pharmaceutical industry, Vaccine

LONDON, Sept. 23, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced it has entered a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult). The collaboration will expand Quell's clinical manufacturing capabilities and capacity in one of the recently opened specialist large-scale manufacturing modules at CGT Catapult's manufacturing innovation centre in Stevenage, UK. This will add a second GMP facility to Quell's manufacturing operations and allow the Company to efficiently develop and scale the production of its novel multi-modular engineered Treg cell therapies for clinical trials.

Key Points: 
  • The collaboration will expand Quell's clinical manufacturing capabilities and capacity in one of the recently opened specialist large-scale manufacturing modules at CGT Catapult's manufacturing innovation centre in Stevenage, UK.
  • The LIBERATE study will be the first Treg based therapy in transplantation aiming to free patients from all systemic immune suppression.
  • The Stevenage Manufacturing Innovation Centre allows companies developing cell and gene therapies to develop their manufacturing processes at scale to Good Manufacturing Practice (GMP) standards.
  • "Quell is a ground-breaking company with leading technology which is progressing engineered Treg cell therapies into the clinic.

Clarity Movement Co. Selected by Greater London Authority to Power New Air Quality Monitoring Network in the Fight Against Toxic Air

Retrieved on: 
Tuesday, January 26, 2021
Air pollution, Climate forcing, Greater London Authority, London, Cities in Europe, Capitals in Europe, Capitals

Clarity's technology will be used in the fight against London's toxic air, giving local communities access to affordable and reliable air quality data at scale.

Key Points: 
  • Clarity's technology will be used in the fight against London's toxic air, giving local communities access to affordable and reliable air quality data at scale.
  • "The Breathe London project makes London the first city to holistically integrate low-cost sensors with existing air quality infrastructure.
  • The U.S. isn't the only country challenged to maintain funding for air quality monitoring infrastructure - government-funded air pollution initiatives are chronically underfunded globally.
  • The Greater London Authority (GLA) is the strategic authority for London and includes the Mayor of London's office.

FS50777422

Retrieved on: 
Friday, February 22, 2019
Transport in London, London, Greater London Authority, London Rail, Transport for London, Crossrail, TfL Rail

The complainant made a multi-part request to Transport for London (TfL) for information about the recruitment procedures of MTR Crossrail. TfL responded to each element of the request, but the complainant remained dissatisfied with some of those responses. Following an internal review TfL’s position is that it does not hold any additional information in respect of the three elements of the request which are the focus of this complaint. The Commissioner’s decision is that TfL does not hold any additional information and is therefore not under a duty, imposed by section 1(1)(b), to communicate that information to the complainant.  Furthermore the Commissioner finds that in respect of the request for a particular job advert, TfL did not hold any information at the time the request was received. Although TfL tried to be helpful by obtaining some relevant information from MTR Crossrail, by failing to make it clear to the complainant that TfL did not hold the job advert itself, TfL has breached section 1(1)(a) of the FOIA. However as the situation has now been clarified in this notice, the Commissioner does not require the public authority to take any further action in respect of this matter.

Key Points: 
  • The complainant made a multi-part request to Transport for London (TfL) for information about the recruitment procedures of MTR Crossrail.
  • TfL responded to each element of the request, but the complainant remained dissatisfied with some of those responses.
  • Following an internal review TfLs position is that it does not hold any additional information in respect of the three elements of the request which are the focus of this complaint.
  • The Commissioners decision is that TfL does not hold any additional information and is therefore not under a duty, imposed by section 1(1)(b), to communicate that information to the complainant.